AR017457A1 - Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias. - Google Patents

Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias.

Info

Publication number
AR017457A1
AR017457A1 ARP990100570A ARP990100570A AR017457A1 AR 017457 A1 AR017457 A1 AR 017457A1 AR P990100570 A ARP990100570 A AR P990100570A AR P990100570 A ARP990100570 A AR P990100570A AR 017457 A1 AR017457 A1 AR 017457A1
Authority
AR
Argentina
Prior art keywords
alkyl
integer
range
independently represent
aryl
Prior art date
Application number
ARP990100570A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26313119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR017457(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9803169.3A external-priority patent/GB9803169D0/en
Priority claimed from GBGB9813533.8A external-priority patent/GB9813533D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR017457A1 publication Critical patent/AR017457A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Abstract

Un compuesto derivado de 2-(purin-9-il)-tetrahidrofuran-3,4-diol de la formula (I), donde R1 y R2 representan independientemente un grupo seleccionado de:cicloalquilo C3-8; hidrogeno; aril2CHCH2-; cicloalquil C3-8-alquilo C1-6; alquilo C1-8;arilaqui lo C1-6; R4R5N-alquilo C1-6; alquil C1-6-CH(CH2OH)-; arilalquilC1-5-CH(CH2OH)-; arilalquil C1-5-C(CH2OH)2-; cicloalquilo C3-8 independientemente sustituido por uno o más grupos -(CH2)pR6; H2NC(=NH)NHCalquilo C1-6; un grupode la formula (II)o tal gru po en el cual un átomo de C de metileno adyacente a X, o tanto si tal existe, se sustituye por metilo; alquil C1-6-OH; haloalquiloC1-8; un grupo de la formula (III); arilo; y -(CH2)fSO2NHg(alquilo C1-4)2-g o -(CH2)fSO2NHg(arilalquilo C1-4)2-g; R3 rep resenta metilo, etilo, -CH=CH2,n-propilo, -CH2CH=CH2, -CH=CHCH3, isopropenilo, ciclopropilo, ciclopropenilo, CH(OH)CH3, -(CH2)qhalogeno, -(CH2)hY(CH2)H, -COO(CH2)H, -CON(CH2)mH((CH2)nH),-CO(CH2)oH, o -C((CH2)uH)=NO(CH2)vH; a y brepresentan independi entemente un numero entero de 0 a 4 con la condicion que a + b esté enla gama de 3 a 5; c, d ye representan independientemente un numero entero de 0 a 3 con la condicion que c + d + e esté en la gama de 2 a 3; f representa 2 o3 y g representa un num eroentero de 0 a 2; p representa 0 o 1; q representa 1 o 2; h representa 1 o 2 e i representa un numero entero de 0 a 1; tal que h + i está enla gama de 1 a 2; jrepresenta un numero entero de 0 a 1 tal que h + i + j está enla gama de 1 a 2; l repres enta 1 o 2; m y n representan independientemente un numero entero de 0a 2 tal que m + n esté en la gama de 0 a 2; o representa un numero entero de 0 a 2; u y v representan independientemente 0 o 1 tal que u + v está en lagama de0 a 1; R4 y R5 repres entan independientemente hidrogeno, alquilo C1-6, arilo, arilaquilo C1-6 o NR4R5 conjuntamente pueden representar piridinilo,pirrolidinilo, piperidinilo, morfolinilo, azetidinilo, azepinilo, piperazinilo o N-alquil C1-6-piperazinilo; R6 representa OH , NH2, NHCOCH3 o halogeno; R7representa hidrogeno, alquilo C1-6, alquil C1-6-arilo o -COalquilo C1-6; X representa NR7, O, S, SO o SO2; aril representa un anillo carbocíclico, bicíclico o
ARP990100570A 1998-02-14 1999-02-11 Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias. AR017457A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9803169.3A GB9803169D0 (en) 1998-02-14 1998-02-14 Chemical compounds
GBGB9813533.8A GB9813533D0 (en) 1998-06-23 1998-06-23 Chemical compounds

Publications (1)

Publication Number Publication Date
AR017457A1 true AR017457A1 (es) 2001-09-05

Family

ID=26313119

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100570A AR017457A1 (es) 1998-02-14 1999-02-11 Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias.

Country Status (32)

Country Link
US (1) US6610665B1 (es)
EP (1) EP1056759B1 (es)
JP (1) JP2002503669A (es)
KR (1) KR20010082512A (es)
AP (1) AP2000001881A0 (es)
AR (1) AR017457A1 (es)
AT (1) ATE223429T1 (es)
AU (1) AU757156B2 (es)
BR (1) BR9907886A (es)
CA (1) CA2319009A1 (es)
CO (1) CO4990969A1 (es)
DE (1) DE69902758T2 (es)
DK (1) DK1056759T3 (es)
EA (1) EA200000759A1 (es)
EE (1) EE200000358A (es)
ES (1) ES2183516T3 (es)
HK (1) HK1032062A1 (es)
HR (1) HRP20000538A2 (es)
HU (1) HUP0100702A3 (es)
IL (1) IL137402A0 (es)
IS (1) IS5576A (es)
MA (1) MA27121A1 (es)
NO (1) NO20004045L (es)
NZ (1) NZ505812A (es)
PE (1) PE20000270A1 (es)
PL (1) PL342396A1 (es)
PT (1) PT1056759E (es)
SK (1) SK12002000A3 (es)
SV (1) SV1999000016A (es)
TR (1) TR200002355T2 (es)
WO (1) WO1999041267A1 (es)
YU (1) YU50800A (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
PE20000270A1 (es) * 1998-02-14 2000-05-20 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
ID29609A (id) 1998-06-23 2001-09-06 Glaxo Group Ltd Turunan 2-(purin-9-il)-tetrahidrofuran-3,4-diol
GB9813565D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
GB9930075D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0115178D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Compounds
WO2003029264A2 (en) 2001-10-01 2003-04-10 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
TWI346109B (en) 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
NZ553288A (en) 2004-08-02 2010-12-24 Univ Virginia 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
PE20080036A1 (es) 2005-10-21 2008-03-06 Novartis Ag Anticuerpos humanos para la interleucina-13 (il13)
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
MX2009004715A (es) 2006-10-30 2009-05-20 Novartis Ag Compuestos heterociclicos como agentes antiinflamatorios.
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
EP2391366B1 (en) 2009-01-29 2012-11-28 Novartis AG Substituted benzimidazoles for the treatment of astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
WO2011022439A1 (en) 2009-08-17 2011-02-24 Intellikine, Inc. Heterocyclic compounds and uses thereof
EP2467383A1 (en) 2009-08-20 2012-06-27 Novartis AG Heterocyclic oxime compounds
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
AP2013007103A0 (en) 2011-02-25 2013-09-30 Irm Llc Compounds and compositions as TRK inhibitors
JP5957526B2 (ja) 2011-09-15 2016-07-27 ノバルティス アーゲー チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
US20150297604A1 (en) 2012-04-03 2015-10-22 Novartis Ag Combination Products with Tyrosine Kinase Inhibitors and their Use
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
ES2831416T3 (es) 2014-07-31 2021-06-08 Novartis Ag Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
PE20000270A1 (es) * 1998-02-14 2000-05-20 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
ID29609A (id) * 1998-06-23 2001-09-06 Glaxo Group Ltd Turunan 2-(purin-9-il)-tetrahidrofuran-3,4-diol

Also Published As

Publication number Publication date
WO1999041267A1 (en) 1999-08-19
HUP0100702A2 (hu) 2002-01-28
IS5576A (is) 2000-07-25
KR20010082512A (ko) 2001-08-30
SK12002000A3 (sk) 2001-07-10
DE69902758T2 (de) 2003-05-15
DE69902758D1 (de) 2002-10-10
CA2319009A1 (en) 1999-08-19
NO20004045D0 (no) 2000-08-11
TR200002355T2 (tr) 2000-11-21
HK1032062A1 (en) 2001-07-06
EP1056759B1 (en) 2002-09-04
HRP20000538A2 (en) 2000-12-31
HUP0100702A3 (en) 2003-01-28
YU50800A (sh) 2003-04-30
NO20004045L (no) 2000-08-11
EE200000358A (et) 2001-10-15
PT1056759E (pt) 2003-01-31
US6610665B1 (en) 2003-08-26
AU2623599A (en) 1999-08-30
PE20000270A1 (es) 2000-05-20
ES2183516T3 (es) 2003-03-16
MA27121A1 (fr) 2005-01-03
JP2002503669A (ja) 2002-02-05
DK1056759T3 (da) 2003-01-06
NZ505812A (en) 2002-03-01
EP1056759A1 (en) 2000-12-06
CO4990969A1 (es) 2000-12-26
AP2000001881A0 (en) 2000-09-30
AU757156B2 (en) 2003-02-06
BR9907886A (pt) 2000-10-17
SV1999000016A (es) 1999-10-27
EA200000759A1 (ru) 2001-04-23
IL137402A0 (en) 2001-07-24
ATE223429T1 (de) 2002-09-15
PL342396A1 (en) 2001-06-04

Similar Documents

Publication Publication Date Title
AR017457A1 (es) Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias.
NZ319131A (en) Herbicidal mixtures having a synergistic effect
CO4980872A1 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
ES2037930T3 (es) Preparaciones acuosas adecuadas como masas de obturacion o adhesivos para baldosas ceramicas.
AR040474A1 (es) Derivados de tiofenolglicosido, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos
AR037929A1 (es) Un compuesto derivado funcional del acido hidroxamico o caloxilico, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento para el tratamiento de trastornos inflamatorios
AR014785A1 (es) Derivados de pirimidina, uso de dichos derivados para la preparacion de medicamentos para el tratamiento de hiv,composicion farmaceutica que los comprende,procedimiento para prepararla, procedimiento para preparar dichos derivados, e intermediarios utiles en la preparacion de dichos derivados.
DK422583D0 (da) Fremgangsmade til fremstilling af diazobicyclo-(3,3,1)-nonaner
SE8002345L (sv) Terapeutiska medel
ATE40688T1 (de) Acridincarboxamid-verbindungen.
ES2045044T3 (es) Derivados de sulfonamidolfenilo y agentes terapeuticos y preventivos de la arritmia que contienen los mismos.
YU47219B (sh) Antivirusna tetrahidroimidazo (1,4) benzodiazepin-2-tiona jedinjenja i postupak za njihovo dobijanje
AR017072A1 (es) Compuestos derivados de pirrolopirrolona como inhibidores de elastasa neutrofilica, uso de dichos compuestos, metodos de tratamiento, procesos depreparacion e intermediarios utiles para su produccion
PE13799A1 (es) Dihidropironas con actividad antiviral
CO4600635A1 (es) Procedimientos e intermedios para preparar derivados de cromanol sustituidos
ATE186302T1 (de) Etoposidanaloge
NO871194L (no) N,n[-substituerte bis-(2,4-diamino-s-triazin-6-yl)-tetrasulfider og deres disproporsjoneringsprodukter, fremgangsmaate til deres fremstilling og deres anvendelse i vulkaniserbare kautsjukblandinger.
GB672971A (en) Improvements in esters and pest-combating agents containing them and in their manufacture
ES8603474A1 (es) Procedimiento para preparar derivados de pirazol 1,5-a-piridina
ZA851127B (en) New 3-phenyl-2-propeneamine derivatives,their preparation and compositions containing them
ES2123739T3 (es) Nuevos analogos del eburnano, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ES2167563T3 (es) Derivados de (2-morfolinilmetil)benzamida.
IL83085A0 (en) Substituted furazans,their preparation and their use as pesticides
SE8100946L (sv) Nya indanderivat, sett att framstella dem, anvendning derav som farmaceutika och farmaceutiska kompositioner som innehaller dess derivat
ES2087955T3 (es) Uso de derivados de 1,2,4-oxadiazol sustituidos para combatir a los endoparasitos, nuevos derivados de 1,2,4-oxadiazol sustituidos y procedimiento para su fabricacion.

Legal Events

Date Code Title Description
FG Grant, registration